STOCK TITAN

Oncolytics Biotech Inc - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.

Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.

Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.

Rhea-AI Summary
Oncolytics Biotech® Inc. announces CEO Dr. Matt Coffey will present at Cancer Advocacy Group of Louisiana's conference. The presentation will take place on March 1, 2024, at the Ritz Carlton Hotel in New Orleans, LA. Company management will also participate in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. expands enrollment for anal cancer cohort in GOBLET study evaluating pelareorep in combination with atezolizumab, showcasing promising clinical data exceeding success criteria. The company aims to address the unmet medical needs in advanced anal cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) announces positive Stage 1 data for pelareorep in combination with atezolizumab in anal cancer cohort of GOBLET study, showing a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response. The expansion of enrollment is supported by strong clinical data exceeding success criteria, potentially opening new treatment options for patients with advanced anal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
none
Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) appoints Patricia S. Andrews to its Board of Directors, a clinical-stage immunotherapeutics company focused on oncology. Ms. Andrews brings extensive board and executive leadership experience and a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations, and business development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
management
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) reported significant 2023 accomplishments, positive clinical and translational data, and anticipated milestones for 2024. The company's cash balance of $40 million supports the initiation of the first Phase 3 study for pelareorep in pancreatic cancer, marking an important inflection point for investors and clinical collaborators. Positive results from Phase 1/2 GOBLET study and HR+/HER2- metastatic breast cancer program demonstrate the potential of pelareorep as an immunotherapeutic agent for various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented translational data from the AWARE-1 breast cancer study at the San Antonio Breast Cancer Symposium. The data showed that pelareorep induced the expansion of Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor, affirming its role as an immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announces positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA). The interim objective response rate (ORR) of 37.5% exceeded historical control trials, showing the potential for pelareorep to offer a new, effective treatment option for patients with advanced SCCA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC). The company will conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study. PanCAN will grant US$5 million for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech announces positive translational data from the AWARE-1 breast cancer study, confirming pelareorep's mechanism of action in the tumor microenvironment. The data shows an increase in PD-L1 positive cells and T cell infiltration after treatment. This supports the use of pelareorep in combination with atezolizumab for metastatic breast cancer and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
Rhea-AI Summary
Oncolytics Biotech announced positive Phase 1/2 survival data for pelareorep in pancreatic cancer. The data showed an objective response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. The company also received a $5 million grant from Pancreatic Cancer Action Network to further evaluate pelareorep in pancreatic cancer. The cash position is $40.0 million with a projected cash runway through critical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
Oncolytics Biotech Inc

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

48.58M
82.87M
4.35%
1.62%
3.44%
Biotechnology
Healthcare
Link
Canada
Calgary